Guardant Health Future Growth
Future criteria checks 1/6
Guardant Health wird ein jährliches Wachstum der Erträge und Einnahmen um 22.6% bzw. 17.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich grow um 25.3% pro Jahr steigen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -41.3% betragen.
Key information
20.5%
Earnings growth rate
26.3%
EPS growth rate
| Healthcare earnings growth | 12.3% |
| Revenue growth rate | 17.1% |
| Future return on equity | -41.3% |
| Analyst coverage | Good |
| Last updated | 02 Apr 2024 |
Recent future growth updates
Recent updates
Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Mar 29
With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For
Jan 21Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Nov 20Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?
Sep 26A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)
Sep 05Is Guardant Health (NASDAQ:GH) A Risky Investment?
Aug 15A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)
May 28Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Apr 05Is Guardant Health (NASDAQ:GH) Using Too Much Debt?
Dec 28Guardant: Saving Lives One Blood Test At A Time
Oct 16Here's Why Guardant Health (NASDAQ:GH) Can Afford Some Debt
Aug 15Guardant Health's test gets FDA win for companion diagnostic to Enhertu's expanded use in lung cancer
Aug 12Guardant Health: Recent Developments Signal More Upsides
Jul 31Guardant Health: Pending Recession, May Hurt Cancer Care Demand
Jul 14Guardant Health (NASDAQ:GH) Is Carrying A Fair Bit Of Debt
Apr 29Guardant Health: Leaping Growth With Epic
Apr 14Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,001 | -334 | -213 | -119 | 12 |
| 12/31/2025 | 803 | -366 | -275 | -193 | 21 |
| 12/31/2024 | 664 | -401 | -318 | -252 | 21 |
| 12/31/2023 | 564 | -479 | -345 | -325 | N/A |
| 9/30/2023 | 536 | -432 | -363 | -337 | N/A |
| 6/30/2023 | 510 | -508 | -383 | -337 | N/A |
| 3/31/2023 | 482 | -665 | -418 | -355 | N/A |
| 12/31/2022 | 450 | -655 | -387 | -309 | N/A |
| 9/30/2022 | 431 | -606 | -388 | -296 | N/A |
| 6/30/2022 | 408 | -551 | -363 | -271 | N/A |
| 3/31/2022 | 391 | -419 | -309 | -221 | N/A |
| 12/31/2021 | 374 | -406 | -284 | -209 | N/A |
| 9/30/2021 | 344 | -409 | -249 | -191 | N/A |
| 6/30/2021 | 324 | -379 | -191 | -146 | N/A |
| 3/31/2021 | 298 | -336 | -143 | -107 | N/A |
| 12/31/2020 | 287 | -254 | -158 | -104 | N/A |
| 9/30/2020 | 271 | -185 | -129 | -75 | N/A |
| 6/30/2020 | 258 | -120 | -118 | -66 | N/A |
| 3/31/2020 | 245 | -77 | -102 | -56 | N/A |
| 12/31/2019 | 214 | -76 | -68 | -47 | N/A |
| 9/30/2019 | 184 | -76 | -60 | -43 | N/A |
| 6/30/2019 | 145 | -87 | -81 | -67 | N/A |
| 3/31/2019 | 111 | -97 | -89 | -70 | N/A |
| 12/31/2018 | 91 | -85 | -92 | -72 | N/A |
| 9/30/2018 | 78 | -75 | -85 | -64 | N/A |
| 6/30/2018 | 67 | -84 | -87 | -68 | N/A |
| 3/31/2018 | 57 | -83 | -77 | -65 | N/A |
| 12/31/2017 | 50 | -89 | -81 | -72 | N/A |
| 12/31/2016 | 25 | -46 | N/A | -37 | N/A |
Analyst Future Growth Forecasts
Einkommen vs. Sparrate: GH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: GH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: GH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: GHDie Einnahmen des Unternehmens (19.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.1% pro Jahr).
Hohe Wachstumseinnahmen: GHDie Einnahmen des Unternehmens (19.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Earnings per Share Growth Forecasts
Future Return on Equity
Künftige Eigenkapitalrendite: GH wird voraussichtlich in 3 Jahren unrentabel sein.